A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

ConclusionThis study demonstrated comparable safety profiles and PK bioequivalence among HLX02, CN-trastuzumab and EU-trastuzumab in healthy Chinese male subjects.Clinical trial registrationClinicalTrials.gov, NCT02581748, registered at October 19, 2015.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research